| human | Q5 |
| P856 | official website | http://iris.ucl.ac.uk/iris/browse/profile?upi=RPATA06 |
| P496 | ORCID iD | 0000-0002-3825-7675 |
| P1053 | ResearcherID | J-3107-2018 |
| P69 | educated at | University of Cambridge | Q35794 |
| Department of Civil and Envionmental Engineering, Imperial College London | Q6006470 | ||
| Imperial College Faculty of Medicine | Q6006478 | ||
| Royal College of Physicians, London | Q16003969 | ||
| P108 | employer | University of Cambridge | Q35794 |
| Addenbrooke's Hospital | Q130282 | ||
| University College London | Q193196 | ||
| National Hospital for Neurology and Neurosurgery | Q3336892 | ||
| Hammersmith Hospital | Q5645747 | ||
| UCL Queen Square Institute of Neurology | Q7864079 | ||
| P106 | occupation | researcher | Q1650915 |
| Q54960388 | A Liquid to Solid Phase Transition Underlying Pathological Huntingtin Exon1 Aggregation. |
| Q42611700 | A neuroprotective astrocyte state is induced by neuronal signal EphB1 but fails in ALS models |
| Q48264691 | Abnormal tau phosphorylation in primary progressive multiple sclerosis |
| Q81489801 | Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis |
| Q33508812 | Activin/Nodal inhibition alone accelerates highly efficient neural conversion from human embryonic stem cells and imposes a caudal positional identity |
| Q35757641 | Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study |
| Q39584699 | Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. |
| Q104102219 | Chloroquine, the Coronavirus Crisis, and Neurodegeneration: A Perspective |
| Q47255098 | Concise Review: The Cellular Conspiracy of Amyotrophic Lateral Sclerosis |
| Q47073859 | Dopamine from the brain promotes spinal motor neuron generation during development and adult regeneration. |
| Q47864330 | Elucidating Pro-Inflammatory Cytokine Responses after Traumatic Brain Injury in a Human Stem Cell Model |
| Q48704378 | Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis |
| Q37388688 | Evidence for evolutionary divergence of activity-dependent gene expression in developing neurons |
| Q36432487 | Experimental and therapeutic opportunities for stem cells in multiple sclerosis |
| Q103749792 | FUS is lost from nuclei and gained in neurites of motor neurons in a human stem cell model of VCP-related ALS |
| Q86495092 | Flexor hallucis brevis spasm |
| Q47428803 | G-quadruplex-binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo. |
| Q26773019 | Generating Diverse Spinal Motor Neuron Subtypes from Human Pluripotent Stem Cells |
| Q90631503 | Harnessing cellular aging in human stem cell models of amyotrophic lateral sclerosis |
| Q26740032 | Human Stem Cell-Derived Astrocytes: Specification and Relevance for Neurological Disorders |
| Q39441131 | Human embryonic stem cell derived astrocytes mediate non-cell-autonomous neuroprotection through endogenous and drug-induced mechanisms. |
| Q24308814 | Human embryonic stem cell-derived neurons as a tool for studying neuroprotection and neurodegeneration |
| Q99208007 | Human stem cell-derived astrocytes exhibit region-specific heterogeneity in their secretory profiles |
| Q33750158 | Human stem cell-derived neurons: a system to study human tau function and dysfunction |
| Q36538815 | Hypothermic Preconditioning Reverses Tau Ontogenesis in Human Cortical Neurons and is Mimicked by Protein Phosphatase 2A Inhibition |
| Q35947718 | Hypothermic Preconditioning of Human Cortical Neurons Requires Proteostatic Priming |
| Q125340950 | Image‐based deep learning reveals the responses of human motor neurons to stress and VCP‐related ALS |
| Q37420398 | In vitro prion-like behaviour of TDP-43 in ALS. |
| Q42760244 | Integrin activation promotes axon growth on inhibitory chondroitin sulfate proteoglycans by enhancing integrin signaling |
| Q55356425 | Intron retention and nuclear loss of SFPQ are molecular hallmarks of ALS. |
| Q36417107 | Investigating the utility of human embryonic stem cell-derived neurons to model ageing and neurodegenerative disease using whole-genome gene expression and splicing analysis |
| Q55083482 | Kir4.1-Dependent Astrocyte-Fast Motor Neuron Interactions Are Required for Peak Strength. |
| Q43131490 | Lymphomatosis cerebri: a treatable cause of rapidly progressive dementia |
| Q112299504 | MIR-NATs repress MAPT translation and aid proteostasis in neurodegeneration |
| Q41848600 | Major Shifts in Glial Regional Identity Are a Transcriptional Hallmark of Human Brain Aging |
| Q112303121 | Meta-analysis of human and mouse ALS astrocytes reveals multi-omic signatures of inflammatory reactive states |
| Q42563477 | Mild oxidative stress activates Nrf2 in astrocytes, which contributes to neuroprotective ischemic preconditioning. |
| Q26749087 | Neural Conversion and Patterning of Human Pluripotent Stem Cells: A Developmental Perspective |
| Q98727294 | Paraspeckle components NONO and PSPC1 are not mislocalized from motor neuron nuclei in sporadic ALS |
| Q33779813 | Progressive Motor Neuron Pathology and the Role of Astrocytes in a Human Stem Cell Model of VCP-Related ALS |
| Q26750561 | Quo vadis motor neuron disease? |
| Q112312817 | Reactive astrocytes in ALS display diminished intron retention |
| Q98199437 | Regionally encoded functional heterogeneity of astrocytes in health and disease: A perspective |
| Q34768963 | Retinoid-independent motor neurogenesis from human embryonic stem cells reveals a medial columnar ground state |
| Q37829160 | Stem cells as a resource for regenerative neurology |
| Q101562545 | Stress-Specific Spatiotemporal Responses of RNA-Binding Proteins in Human Stem-Cell-Derived Motor Neurons |
| Q48127466 | TS or not TS? |
| Q98727283 | The FUS about SFPQ in FTLD spectrum disorders |
| Q102329379 | The FUS gene is dual-coding with both proteins contributing to FUS-mediated toxicity |
| Q34686955 | The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments |
| Q37666286 | The translational potential of human induced pluripotent stem cells for clinical neurology : The translational potential of hiPSCs in neurology |
| Q52317296 | Three-Dimensional Human iPSC-Derived Artificial Skeletal Muscles Model Muscular Dystrophies and Enable Multilineage Tissue Engineering. |
| Q36357156 | Using human induced pluripotent stem cells to model cerebellar disease: hope and hype. |
| Q37979571 | Using human pluripotent stem cells to study post-transcriptional mechanisms of neurodegenerative diseases |
| Q37963576 | Using induced pluripotent stem cells (iPSC) to model human neuromuscular connectivity: promise or reality? |
Search more.